semaglutide compounding fda enforcement today Troubling Findings in Study of GLP-1 Compounders Compounded semaglutide: What should patients

The Power of Advocacy and Legal Action *Best Practices for Health Care Businesses: Follow all HIPAA guidelines for all patients or clients

For the best results, pair supplementation with hydration and a balanced diet

They do not compete for the same receptors, and they are processed by the body in different ways

ET Saturday, June 6 DALLAS, JUNE 6, 2026 Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association , an open-access, peer-reviewed journal of the American Heart Association